Please login to the form below
Quell Therapeutics
This page shows the latest Quell Therapeutics news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca and Quell announce autoimmune disease partnership worth over $2bn
AstraZeneca (AZ) and Quell Therapeutics have announced a collaboration agreement focused on developing cell therapies for two autoimmune disease indications, with the deal potentially worth over $2bn. ... The partnership will utilise Quell’s
Latest news
-
Syncona start-up Quell Therapeutics appoints chief exec
Biotech focusing on Tregs. Quell Therapeutics, a new UK biotech company focused on developing engineered T regulatory (Treg) cell therapies, has appointed Iain McGill as its chief executive. ... London-based Quell Therapeutics aims to harness this
-
Syncona launches another cell therapy company, Treg specialist Quell
Focuses on novel immune system approach. Syncona has invested £34m ($43m) in start-up financing for Quell Therapeutics, a cell therapy company focusing on using T regulatory (Treg) cells to treat ... Another of its start-ups, gene therapy specialist
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Actinic keratosis – a common skin condition that can lead to skin cancer
- The paper trail
- Medscape Education’s Large Presence at IDWeek 2023
- WHO recommends second malaria vaccine for children
- Sanofi enters agreement with Janssen to develop E. coli vaccine candidate
- NFID and CDC urge US adults to get vaccinated against flu and COVID-19
No results were found
PMHub
AMICULUM
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...
Latest intelligence
- Actinic keratosis – a common skin condition that can lead to skin cancer
- PMGroup talks to Volker Koscielny, Chief Medical Officer at Almirall, about the importance of remaining vigilant about skin checks, the prevalence of actinic keratosis in the UK and the steps...
- Man vs microbe: the fight against antimicrobial resistance
- How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
- Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
- Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...
